Navigation Links
Joyant-Licensed Technology Earns Broad Patent Protection
Date:2/15/2011

DALLAS, Feb 15, 2011 /PRNewswire/ -- Joyant Pharmaceuticals Inc. ("Joyant"), a privately-held pharmaceutical company, announced the grant of an exceptional US patent covering an entire class of anti-cancer therapeutics based upon Smac mimetics.  Smac mimetics represent a novel approach to targeting the apoptotic pathway and have broad potential for the treatment of cancer, both solid tumor and hematological malignancies.

The United States Patent and Trademark Office (USPTO) granted US Pat. No. 7,884,211 on Joyant's exclusively-licensed anticancer drug technology.  "The USPTO issues broad claims like this only for truly pioneering inventions," noted Richard Aron Osman, JD, PhD, of the Science and Technology Law Group, the patent attorney responsible for prosecuting the patent application.

"Smac" is a natural protein that triggers the destruction of cancer cells. Researchers at UT Southwestern Medical Center serendipitously discovered that dimeric small molecule Smac mimics are extremely effective killers of cancer cells.  Joyant Pharmaceuticals, the exclusive licensee of this UT Southwestern technology, is actively developing Smac mimetics as anti-cancer therapeutics.

"We are very pleased with the scope of this issued patent.  It is a testament to the innovation and potential in our Smac mimetic program," said Dr. Lai Wang, Director of Research at Joyant.

"It is one of our most promising development platforms, with outstanding lead compounds."

About Joyant

Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Joyant is actively translating the molecular pathways that control the growth, replication, and apoptosis of human cells into signaling-based targeted therapeutics.  Joyant has the financial backing of Sanderling Ventures.


'/>"/>
SOURCE Joyant Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Proventix Helps Princeton Baptist Medical Center Earn National Recognition from HIMSS/ASQ for Quality Improvement Using Information Technology
2. Reportlinker Adds Global Anti-counterfeit Markets in Food & Pharmaceutical Applications by Geography, Technology Trends and Forecasts (2010-2015)
3. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
4. Abbotts Ibis Technology Identified Fatal Disease Organism in Afghanistan
5. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
6. Endologix Announces Favorable Clinical Results for Nellix Technology
7. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
8. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
9. Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
10. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
11. Crestwood Technology Group Receives Silver Boeing Performance Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):